title: IL-33 is regulated by TNF-α in normal and psoriatic skin.
abstract: Interleukin-33 (IL-33) is the most recently discovered IL-1 family member. Considered an endogenous "alarmin" released by necrotic cells in response to tissue injury or damage, IL-33 is constitutively expressed in tissues exposed to the environment, where endothelial and epithelial cells constitute its major sources. Several findings reported that pro-inflammatory stimuli, such as IFN-γ and TNF-α, as well as IL-17, can induce IL-33 expression in normal human epidermal keratinocytes. In the present study, we deeply investigated the relation between IL-33 and TNF-α, by employing the whole skin as study model. TNF-α dose- and time-dependently induced IL-33 gene expression in ex vivo healthy skin organ culture. Similarly, TNF-α significantly increased IL-33 mRNA expression in normal human epidermal sheets. Moreover, IL-33 was enhanced in psoriatic skin and anti-TNF-α therapy was able to significantly reduce it. The biology of IL-33 is gaining in complexity, and this molecule is now known to have additional roles beyond its original description. In particular, we can assess that IL-33 is regulated by TNF-α in normal and psoriatic skin.
authors: Department of Dermatology, University of Naples Federico II, Via S. Pansini, 5, 80131, Naples, Italy, annabalato@yahoo.it.
authors: Anna
authors: A
authors: Balato
authors: Roberta
authors: R
authors: Di Caprio
authors: Luigi
authors: L
authors: Canta
authors: Martina
authors: M
authors: Mattii
authors: Serena
authors: S
authors: Lembo
authors: Annunziata
authors: A
authors: Raimondo
authors: Maria
authors: M
authors: Schiattarella
authors: Nicola
authors: N
authors: Balato
authors: Fabio
authors: F
authors: Ayala
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D000067596:Interleukin-33; D007378:Interleukins / Q000235:genetics / Q000378:metabolism*; D009924:Organ Culture Techniques; D011565:Psoriasis / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D012867:Skin / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D015854:Up-Regulation
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C506536:IL33 protein, human; D018836:Inflammation Mediators; D000067596:Interleukin-33; D007378:Interleukins; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab